Neumora Therapeutics (NMRA) Investor presentation summary

Mission and leadership

• Focus on developing next-generation, brain-penetrant therapies to improve outcomes and quality of life for patients with neurological and psychiatric disorders.

• Led by experienced executives and board members with backgrounds in major pharmaceutical and biotech companies.

Strategic focus and market opportunity

• Targeting large unmet needs in neurodegenerative, neuropsychiatric, and metabolic diseases, including Alzheimer's, Parkinson's, schizophrenia, and obesity.

• Addressing markets with millions of affected patients and significant growth potential, such as Alzheimer's agitation and obesity.

Pipeline and clinical programs

• Advancing three core franchises: neurodegenerative (NMRA-511, NMRA-GCASE, NMRA-CK18), neuropsychiatric (NMRA-898), and metabolic (NMRA-215).

• Multiple clinical milestones expected in 2026, including Phase 2 initiation for NMRA-511, Phase 1 data for NMRA-898, and clinical entry for NMRA-215.